• Publications
  • Influence
Metabolic Modulation of Glioblastoma with Dichloroacetate
Dichloroacetate appears to be safe to give to humans at doses that are required for pyruvate dehydrogenase inhibition, and can be added to a growing group of metabolic modulators that may prove useful in cancer therapy.
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
The generic drug dichloroacetate is an orally available small molecule that reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo.
Inflammation, growth factors, and pulmonary vascular remodeling.
The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted
The generalized activation of NFAT in human and experimental PAH might regulate the ionic, mitochondrial, and inflammatory remodeling and be a therapeutic target and biomarker.
An Abnormal Mitochondrial–Hypoxia Inducible Factor-1&agr;–Kv Channel Pathway Disrupts Oxygen Sensing and Triggers Pulmonary Arterial Hypertension in Fawn Hooded Rats: Similarities to Human Pulmonary
An intersection between oxygen-sensing mechanisms and PAH is revealed, analogous to the pathophysiology of chronically hypoxic Sprague-Dawley rats, and the mitochondria-ROS-HIF-Kv pathway offers new targets for PAH therapy.
Diversity in Mitochondrial Function Explains Differences in Vascular Oxygen Sensing
Differential regulation of a tonically produced, mitochondria-derived, vasodilating factor, possibly H2O2, can explain the opposing effects of hypoxia on the PAs versus RAs.
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility
The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.
Vascular Endothelial Growth Factor Gene Therapy Increases Survival, Promotes Lung Angiogenesis, and Prevents Alveolar Damage in Hyperoxia-Induced Lung Injury: Evidence That Angiogenesis Participates
These findings underscore the importance of the vasculature in what is traditionally thought of as an airway disease and open new therapeutic avenues for lung diseases characterized by irreversible loss of alveoli through the modulation of angiogenic growth factors.